Status:
COMPLETED
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Lead Sponsor:
Shire
Conditions:
Thrombocythemia, Hemorrhagic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots. When patien...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of essential thrombocythaemia - high risk profile
- Previously untreated with a cytoreductive agent
- Females of childbearing potential must have a negative urine pregnancy test prior to entering the study and must agree to use effective birth control for the duration of the study
Exclusion
- Diagnosis of any other myeloproliferative disorder
- Any known cause for a secondary thrombocytosis
- Anti-coagulant and anti-aggregant therapies
- Known or suspected heart disease
- Left Ventricular Ejection Fraction \< 55%
Key Trial Info
Start Date :
January 13 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00202644
Start Date
January 13 2006
End Date
December 15 2015
Last Update
June 2 2021
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven
Pleven, Bulgaria, 5800
2
University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology
Sofia, Bulgaria, 1303
3
University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic
Varna, Bulgaria, 9010
4
CHU Angers Services des Maladies du Sang
Angers, Cedex 09, France, 49933